Business Wire

Tax Systems Acquires Loctax to Further Strengthen Its Position in the European Tax SaaS Market

8.10.2025 10:00:00 CEST | Business Wire | Press Release

Share

Tax Systems, a global tax and accounting software provider, has today announced the acquisition of Loctax, a leading provider of collaborative tax, compliance, risk and governance solutions for in-house global tax teams. The acquisition will enable Tax Systems to deliver on its goal of becoming EMEA’s leading SaaS tax compliance platform and will significantly accelerate the development of its product roadmap.

Loctax is the first-ever AI tax control centre that helps finance and tax teams automate compliance processes, manage risks and centralise data across all jurisdictions and tax types. Loctax brings together everything from monitoring filings and deadlines to workflows, business support and reporting, powered by AI agents that reduce manual effort.

By bringing Loctax into its portfolio, Tax Systems adds a category-defining solution that delivers the first context-aware, integrated workflow across multiple tax processes. In addition, Loctax has already embedded agentic AI in real-world use cases, complementing the existing Tax Systems products to create a powerful end-to-end platform that provides tax teams with greater oversight, automation, and assurance.

Leveraging the latest innovations in cloud and AI, the integration of the two companies’ solutions represents a significant milestone in Tax Systems’ commitment to its vision of 'one platform, total control'. For customers, the acquisition will deliver enhanced control over their tax operations. In addition to compliance, they can gain complete visibility of their data and obligations, with the confidence that all aspects of their tax function are connected and securely managed.

“This acquisition is an exciting milestone for Tax Systems,” said Bruce Martin, CEO of Tax Systems. “Loctax has created the first true tax control centre, and integrating it with our existing solutions will allow us to deliver a more comprehensive platform for tax teams. It will also significantly strengthen our market position, enabling our customers to manage their tax obligations with confidence and the advanced capabilities required. We look forward to working closely with the Loctax team.”

“Joining forces with the Tax Systems team felt like a logical next step for Loctax,” said Stevi Frooninckx, CEO of Loctax. “Our AI tax control centre can now integrate with the tax engines in the Tax Systems product portfolio, to provide end-to-end visibility and control over tax jobs like Pillar Two or the tax provision process. Together we will define the tax function of the future, and empower leading tax teams to have the highest levels of preparedness for any upcoming challenges.”

Loctax will continue to operate under its own brand as “a Tax Systems company” during the transition period, ensuring continuity for customers while benefiting from the scale and backing of Tax Systems. Its go-to-market and product teams will report into Tax Systems, maintaining close engagement with existing customers. At the same time, dedicated resources have been allocated to integrate Loctax’s platform with Tax Systems’ wider suite, unlocking the full power of the combined offering.

About Tax Systems

Tax Systems, a Providence Equity Partners (“Providence”) backed business, is a global multi-tax compliance SaaS provider, with market-leading solutions across the UK, Ireland, Europe, and the UAE. Its solutions digitise tax processes and revolutionise compliance operations, enabling tax professionals to create better opportunities and generate valuable insights from their tax function while also mitigating risk. Translating complex, ever-changing tax legislation into intuitive solutions, customers can trust that their calculations will be right, first-time, every time.

Founded in 1991, Tax Systems has over 30 years’ experience and works with over 42% of the FTSE 100 and 80% of the top advisory firms in the UK and Ireland, where more than 30,000 tax professionals are trained to use their solutions, filing over 200,000 submissions every year.

About Loctax

Loctax is the first AI tax control centre for global tax operations. It gives in-house finance and tax teams one place to manage global tax obligations, monitor KPIs and orchestrate collaboration in an autonomous and secure platform that helps teams stay ahead of surprises. With Loctax, teams centrally manage workflows with clear roles and responsibilities. Legal, tax and financial data is captured and stored, leaving a guaranteed audit trail.

Built-in AI uses company-specific data with trusted tax regulatory content to give accurate answers and practical support. It classifies documents and extracts data in multiple languages and links them to the right entity and period. Agents can manage incoming emails and create tasks to execute. The result is solid compliance, stronger control and effective business support, putting tax in a strategic seat.

Founded in 2020 in Belgium and backed by Europe’s leading VCs, including Index Ventures, Seedcamp and NAP.vc, Loctax serves customers from high-growth innovators to the world’s biggest enterprises.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251003922428/en/

Contacts

Media
Touchdown PR
Taxsystems@touchdownpr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye